Development of Reports and Visualisations to Facilitate the Analysis and Transformation of the Clinical Trial Landscape into Actionable Intelligence

II-SDV 2014

AstraZeneca – Jasen Chooramun, Jeanette Eldridge & So Man

BizInt – Diane Webb, Matt Eberle & John Willmore

AstraZeneca 秋

Agenda

Generic process

- Data Sources
- Toolkit

Clinical Trial Scenarios

- Collaborations
- Mapping Locations
 - US and UK Geocoding
- Visualising Timelines

•Data Issues

•Wish list

Closing Remarks





Process What are Clinical Trials?

•Regulated study used to determine whether a treatment or device is safe and effective in humans

•In this presentation we have used two sources of Clinical Trial Information:

ClinicalTrials.gov





4 Jasen Chooramun | April 2014

Process Toolkit

•BizInt Smart Charts for Drug Pipelines

• Import results from each database and combine

BizInt Smart Charts Reference Rows

- Create a single row and summarize indications for each trial
- VantagePoint Smart Charts Edition
 - Normalize phases
 - Clean up sponsors
 - Create visualization





Clinical Trial Scenarios Analysis & Visualisation

Collaboration is a way of life across our business

Clinical Trial Collaborations Background

Can we use clinical trials data to identify potential collaboration opportunities in a particular region?

ClinicalTrials.gov "esophageal cancer" OR "oesophageal cancer" OR "oesophogeal cancer" (703 hits) \rightarrow Region Name \rightarrow Europe [map] \rightarrow UK (39 hits)

Citeline TrialTrove Oncology \rightarrow Esophageal \rightarrow Location:UK (185 hits)





703 studies found, shown on map.

A similar map is available for all studies in ClinicalTrials.gov

Click on the map below to show a more detailed map (when available) or search for studies (when map not available).



Clinical Trial Collaborations ClinicalTrials.gov – Aduna Cluster Map

Limited clean-up using VP-SCE on small set of data from ClinicalTrials.gov does not provide a lot of insight into pharma company connections to research and academic institutions

Jasen Chooramun | April 2014

11



Clinical Trial Collaborations Citeline TrialTrove

 Visualisation of larger answer set in TrialTrove shows many more relationships

12



Clinical Trial Collaborations Search Learnings

•Citeline provided significantly higher recall than CT.gov

•Example: NCT00809133 does not mention 'esophageal cancer' at all in the CT.gov record, corresponding CTT record is indexed for this condition and notes in "Patient Population"

"2009 ASCO Annual Meeting Sixteen patients (6 male/10 female; median age: 59 [range: 39-72]; ECOG PS 0/1: 5/11). Patients with non-small cell lung cancer (3), prostate cancer (1), oesophageal cancer (1) and cholangiocarcinoma (1). "

•CT.gov data includes relatively clean post code data so can be displayed down to UK county level

•XML from CT.gov has better structure for accessing this information

•TrialTrove data includes post code data but the information is buried in free text

•How can we leverage recall of CTT with structure of CT.gov?



13 Jasen Chooramun | April 2014

Extracting trials from ClinicalTrials.gov

Ci	teline TrialTrove: trialtrove	e_2675925
	Trial Title	Trial Identifier
51	A Phase I Open Label Trial of Continuous Dosing With BIBW 2992 Combined With Paclitaxel and BIBW 2992 Combined With Paclitaxel and Bevacizumab, BIBW 2992 Combined With Carboplatin and BIBW 2992 Combined With Paclitaxel and Carboplatin in Patients With Advanced Solid Tumours	1200.12 BIBW 1200.12 EudraCT Number: 2006-005005-55 NCT00809133 TrialTroveID-102 148
52	A Phase I Clinical Trial of CXR 1002 in Patients With Advanced Cancer.	SA125 TrialTroveID-102 948
	A Phase I Dose Escalation Study of MK-2206 in	003-00 003: MK-2206
" E	Export all tria	I IDs



16 records at a time

http://www.clinicaltrials.gov/ct 2/results?id=NCT00002615+O R+NCT00003698+OR+NCT000 04236+OR+NCT00041262+OR+ NCT00072332+OR+NCT000735 02+OR+NCT00080002+OR+NC T00087503+OR+NCT00090207 +OR+NCT00113581+OR+NCT0 0169520+OR+NCT00193882+O R+NCT00215644+OR+NCT002 20064+OR+NCT00220103+OR+ NCT00220129&studyxml=true



14 Jasen Chooramun | April 2014

Clinical Trial Locations Geographical Mapping Searches, process and learnings

ClinicalTrials.gov (CT.gov), basic search: Sjogrens

Citeline TrialTrove (CTT), disease field: Sjogrens

Database	No. of trials	Unique counts
CT. gov	69	58
CTT	162	135

Overlap 34 trials





Clinical Trial Locations Geographical Mapping Geo mapping at country level- 'quick' solutions

CT.gov



US State View



VP-SCE: Integration of data - country level





Clinical Trial Locations Geographical Mapping Geomapping- multiple databases at city level





State extracted from all trials but one

	Trial	Investigators / Contacta		Location De	etails	
	Locations	investigators / contacts	Faciliy	Country	City	Post Code
Solution Solution	Bulgaria Europe Israel Romania United States	Michael H Silverman, MD, Study Director Can-Fite BioPharma Assaf Harophe Zrifin, Israel Contact: Sari Fishman, PhD Bnei Zion Medical Center Haifa, Israel, 31048 Phone: +972-3-9241114 E-mail: sari@canfite.co.il Can-Fite BioPharma, Responsible Party				
1 1 <th1< th=""> <th1< th=""> <th1< th=""> <th1< th=""></th1<></th1<></th1<></th1<>	Israel	Roger Vogel, MD Study Chair Sirion Therapeutics Darin Brimhall, DO Principal Investigator Novum Pharmaceutical Research Services Daniel V Freeland, DO Principal Investigator CEDRA Clinical Research, LLC Roger Vogel, MD Study Chair Rx Development Resources, LLC Terry Laliberte, BS Study Director River Plate Biotechnology, Inc. Charles (Andy) Kirby, MD Principal Investigator Chattanooga Eye Institute, Chattanooga, TN Mark Abrams, MD	Bnei Zion Medical Center	Israel	Haifa	31048

Potential Pitfalls of Keyword Extraction

Field Name				Value			
Common Trial ID	TrialTrovalD 185670						
Discaso	Siggrop's Syndromo						
Investigators / Contacts	Yumi Yamaguchi, Keishi F Japan	⁻ ujio, Hirofumi Shoda, Akiko O	kamoto, Mihoko Shibu	iya, Shuji Sumitomo, K	azuhiko Yamamot	o Department of Allergy and Rheumat	tology, The University of Tokyo,
Primary Drugs	pilocarpine, MGI						
Primary Endpoints	2013-04-18						
reported	com bizcharts: C#/Ucors/m			chrr:TDOV/E:195670			
Spopaorahin	(Other Hespital/Academic	Medical Center)		CIII. I KOVL. 103070			
Target Accrual	N/A						
Trial Identifier	TrialTrovelD-185670						
Trial Locations	Janan						
Trial Objectives	To investigate the effect of	f pilocarpine hydrochloride ag	ainst the morning veros	stomia with signren's s	vndrome natients	To evaluate sleep disruption to count	the waking times due to water
mar objectives	intake, morning xerostomi	a, oral pain and sticky mouth f	eeling using the VAS s	cale on days 1 and 28	, sharonne patients.	To evaluate sleep disruption to count	the waiting times due to water
Trial Phase	IV	a, oral part and cuory mount		ould on dujo 1 und 20			
Trial Status	Completed						
Trial Title	Efficacy of pilocarpine hyd	drochloride for dry mouth in the	morning with Sjogren'	s syndrome			
Investigators / Contacts :	Tokyo	· · ·					
Japan prefectures							
	Yamaguchi						
1	10-1-1		Location Dett	ino -		04-4- 0T-TT	
Investigators	s/Contacts	E ili-	0	014	Dest Octo	State C1+11	
		Faciliy	Country	City	PostCode		
Dr John C Davis Clinica Division of Rheumatolo	al Trials Center, 🛛 💙 ogy, University of				×	California	♥
California, San Francis	co, 533 Parnassus						
Avenue Box 0633 Roon	n U383. San Francisco.						
CA94143-0633 USA F	-mail -						
idavis@medicine ucsf	edu B Gescuk, S Lund						
K Eve Division of Rheur	matology University of						
California San Francis	co California LISAA I						
Wu LP Whitcher TED	aniele The Siögren's						
Syndromo Clinic Univo	valitets The Sjogren's						
Syndrome Clinic, Onive	isity of California, San						
Francisco							
Principal Investigator: L	Darin Brimhall, DO 🛛 🗸				· · · · · · · · · · · · · · · · · · ·	Nevada	♥
Novum Pharmaceutica	Research Services						
Las Vegas, Nevada, Un	nited States, 89121						
Responsible Party: Roy	kane Laboratories						
Athena S. Papas DMD.	PhD Department: 🖌				v	Florida	~
General Dentistry - Den	ntal Tufts University				· · · · · · · · · · · · · · · · · · ·	Mississippi	*
Dental Health Schl-1 Ki	neeland Boston						
Phone: (617) 636-3032	Pager: (617)						
604-4234 Fov: (617) 62	6-4083 Empil Address						
athona nanae@tuffe.or	u Dr. Wonne S						
	RIA 5333 N Divio						
Lindwoy Quite 140 Ft	Louderdele Eleride						
Fighway, Suite 110, Ft. I	Lauderdale, Florida						
33334 Phone: 954-229	9-7030 Charney,						
Michael MD; Golden, Ha	arvey E. MD; Medsger,						
Thomas A. Jr MD; Wals	h, Bridget T. DO;						
Trivedi, Madhu PhD, ME	BA; Goldlust, Barry PhD;						descriptor Sub level 1
Gallagher, Susan C. MS	S, MBA						

VP-SCE Extract States to build a Map with Google Geocharts



ClinicalTrials.gov: Select UK sites and postcodes

Location Details:

SO16 6YD

ME16 9QQ 1 TR1 3LJ 5

HA6 2RN 1 LL18 5UJ 9 SW3 6JJ 5 G12 0YN 4 AB25 2ZN 4 BS2 8ED 4 CB2 2QQ 1 HD3 3EA 1 NE29 8NH 3 BT9 7AB 3 CF14 2TL 1 NG5 1PB 1 PE3 6DA 1 WC1E 6BT 2 BH15 2JB 2 CA2 7HY 2 CH63 4JY 2 DD1 9SY 2 DN2 5LT 2 EC1A 7BE 2 EH4 2XU 2 GL1 3NN 1 LE7 5WW 1 LS16 6QB 1 NG7 2UH 1 NW1 2PQ 1 PR8 6PN 2 SL2 4HL 1 S014 0YG 1 TA1 5DA

Instance:

6

4

				Locatio	n Details				
	# Records	# Instances	Faciliy	Country	City	Post Code	UK		
1	4	4	Aberdeen Royal Infir	United Kingdom	Aberdeen, Scotland	AB25 2ZN	$\overline{\mathbf{v}}$		
2	4	4	Royal Marsden Hosp	United Kingdom	Sutton, Surrey	SM2 5PT		1	6
3	3	3	Addenbrooke's Hosp	United Kingdom	Cambridge, England	CB2 2QQ		2	L,
4	3	3	Bristol Haematology a	United Kingdom	Bristol, England	BS2 8ED		2	4
5	3	3	Novartis Investigative	United Kingdom	Glasgow	G12 0YN		3	1
6	3	3	Novartis Investigative	United Kingdom	Sutton	SM2 5PT		4	5
7	3	3	Research Site	United Kingdom	London			5	1
8	3	3	Research Site	United Kingdom	Manchester			6	9
9	3	3	Research Site	United Kingdom	Sutton			7	5
10	3	3	Southampton Genera	United Kingdom	Southampton, Englan	SO16 6YD		8	4
11	3	3	St. Luke's Cancer Ce	United Kingdom	Guildford, England	GU2 7XX		9	4
12	3	3	Velindre Cancer Cen	United Kingdom	Cardiff, Wales	CF14 2TL		10	
13	2	2	Aintree University Ho	United Kingdom	Liverpool, England	L9 7AL		10	-
14	2	2	Christie Hospital	United Kingdom	Manchester, England	M20 4BX		11	1
15	2	2	Clatterbridge Centre	United Kingdom	Merseyside, England	CH63 4JY	$\overline{\mathbf{v}}$	12	1
16	2	2	Cumberland Infirmary	United Kingdom	Carlisle, England	CA2 7HY		13	3
17	2	2	Derriford Hospital	United Kingdom	Plymouth, England	PL6 8DH		14	3
18	2	2	Doncaster Royal Infir	United Kingdom	Doncaster, England	DN2 5LT	7	15	1
19	2	2	Dorset Cancer Centr	United Kingdom	Poole Dorset, Englan	BH15 2JB		16	1
20	2	2	Gloucestershire Roy	United Kingdom	Gloucester, England	GL1 3NN	$\overline{\mathbf{v}}$	17	1
21	2	2	GSK Investigational S	United Kingdom	London	W12 0HS		18	2
22	2	2	Leicester Royal Infirm	United Kingdom	Leicester, England	LE1 5WW		10	2
23	2	2	Lincoln County Hosp	United Kingdom	Lincoln, England	LN2 5QY		19	4
24	2	2	Ninewells Hospital	United Kingdom	Dundee, Scotland	DD1 9SY		20	2
25	2	2	Northern Centre for (United Kingdom	Newcastle-Upon-Tyr	NE4 6BE		21	2
26	2	2	Novartis Investigative	United Kingdom	Oxford	OX3 7LJ	Ī	22	2
27	2	2	Novartis Investigative	United Kingdom	Sutton, Surrey	SM2 5PT		23	2
28	12	2	Research Site	United Kingdom	Guildford		눈	24	2
29	2	2	Research Sile	United Kingdom	Glasyuw		i v	25	2
30	2	2	Research Site	United Kingdom	Wolverhampton			26	4
31	2	2	Roval Marsden - Sur	United Kingdom	Sutton, England	SM2 5PT	Ī	20	Ľ
32	2	2	The Christie NHS Fou	United Kingdom	Manchester	M20 4BX		21	1
33	$\frac{1}{2}$	2	University Hospitals	United Kingdom	Leicester, Leicesters	LE1 5WW		28	1
34	$\frac{1}{2}$	2	Wexham Park Hospit	United Kingdom	Slough, Berkshire, Fr	SL2 4HL		29	1
35	11	1	1200.12.4401 Boehri	United Kingdom	Sutton			30	1
36	11	1	1200 12 4402 Boehri	United Kingdom	London		÷	31	2
37	1 i	1	1200 24 4401 Boehri	United Kingdom	Sutton		F	32	1
38	H-	1	1200.24 4402 Boehri	United Kingdom	London		÷.	33	1
00	÷	Ŀ	1000.01.1100.D		0.117.1				H



Set area descriptor | Sub level 1

Jasen Chooramun | April 2014 22

We can use a thesaurus to check for data-entry errors in ClinicalTrials.gov data

			ails:	🚳 Thesaurus Editor
	ę	ces	Det	File Edit Thesaurus
	# Recor	# Instan	Locatio	
1	6	6	S016 6YD	- Field
2	4	4	ME16 9QQ	india incodutas incodutas
3	1	1	TR1 3LJ	Location Details:UK:11 📻 👔 C:\Program Files (x66)\VantagePoint-SCE\Thesaurus\UK F 🛛 Apply Thesaurus
4	5	5	HA6 2RN	
5	1	1	LL18 5UJ	
6	9	9	SW3 6JJ	
7	5	5	G12 0YN	
8	4	4	AB25 2ZN	
9	4	4	BS2 8ED	BD BD
10	4	4	CB2 2QQ	WIT 3AA
11	1	1	HD3 3EA	BD BN
12	1	1	NE29 8NH	i i i i i i i i i i i i i i i i i i i
13	3	3	BT9 7AB	
14	3	3	CF14 2TL	R CA
15	1	1	NG5 1PB	BR CB
16	1	1	PE3 6DA	The BS
17	1	1	WC1E 6BT	
18	2	2	BH15 2JB	
19	2	2	CA2 /HY	
20	2	2	CH63 4JY	
21	4	2	DN2 ELT	
22	2	2	EC1A 7RE	Display
23	2	2	EUTA /BE	
25	2	2	GL1 3NN	Entire List
26	1	1	LET 5WW	
27		1	LS16 6QB	Matched Terms
28		1	NG7 2UH	In-Matched Terms
29	1	1	NW1 2PQ	
30	1	1	PR8 6PN	
31	2	2	SL2 4HL	
32	1	1	S014 0YG	
33	1	1	TA1 5DA	
	1.		···	1



23 2|3

TrialTrove: VP-SCE Used to Extract Postcodes

					ords	ance:	ligato		ords	ances	stcod	
					# Rec	# Inst	Invest		# Rec	# Inst	ž	
				1	36	36	SM2 5PT	1	51	64	SM	1
		Ses		2	9	9	M20 4BX	2	20	23	M	1
	DIO:	tan		3	7	7	OX3 7LJ	3	17	18	G	1
	Rei	lins		4	5	5	BT9 7AB	4	16	16	SW	1
82	1	1	Chief Investigator: Prof David C	5	5	5	FC1V 4AD	5	13	13	0X	
83	1	1	Claire Harrison1, Richard M. Pa	6	5	5	LE1 5WW	6	12	13	LE.	
84	1	1	Clinical Trials	7	5	5	NW/1 2DA	7	10	12	CB	-
85	1	1	Clinical Trials, Study Director H	0	5	5	WOOA 2DV	0	10	10	NW	-
87	1	1	Contact: Alex Jonson Campridg	0	10	5		0		0	PT	-
88	1	1	Contact: Boehringer Ingel	9	4	4	G11 6N1	9	3	9	51	-
89	1	1	Contact: Chugai Pharma E	10	4	4	HA6 2RN	10	9	9	LS	
90	1	1	Contact: ImClone Systems	11	4	4	WV10 0QP	11	9	9	NE	
91	1	1	Contact: Novartis Pharma	12	3	3	CB2 0QQ	12	9	10	W	
93		1	Contact: Ph: 888-662-672	13	3	3	CF14 2TL	13	8	8	BS]
94	1	1	Contact: Trial Manager Ph	14	3	3	LS2 9LT	14	8	9	HA	1
95	1	1	Daniel Chen, M.D., Ph.D. C	15	3	3	NE2 4HH	15	8	10	SO	1
96	1	1	David Cunningham, M.D. [16	3	3	S016.6VD	16	8	9	WC	
98		1	David Ferry Department o	17	5	2	BS2.8ED	17	8	q	WV	
99	1	1	David Ilson MD, PhD; Princ	17	4	4	D52 0ED	40	17	0	50	-
100	1	1	David J Bowrey, MD Stud	18	4	2	DE22 3NE	10	<u>'</u>	0		-
101	1	1	David Sternberg, MD, PhD	19	2	2	G12 0YN	19	1	1	GU	
102	1	1	Dr A Maraveyas, Acaden	20	2	2	G61 1BD	20	6	7	CF	
103		1	Dr Andrew Jackson Southamp	21	2	2	SM2 5NG	21	5	5	SE	
105	1	1	Dr Anne Thomas, Study invest	22	2	2	SW3 6JJ	22	4	4	AB	1
106	1	1	Dr Brian Haylock, Clatterbridge	23	2	2	W12 0NN	23	4	7	В	1
107	1	1	Dr Chris Baughan; Chief Invest	24	1	1	B18 7QH	24	4	4	EH	1
109		1	Dr D J Girling, MRC Clinical Trial	25	1	1	B29.6.ID	25	4	4	ME	1
110	1	1	Dr D. Cunningham, Gl and Lym	26	1	1	BD7 1DP	26	2	3	CH	-
111	1	1	Dr Daniel Hochhauser, Cancer	20	4	4		20	2	2	CV CV	-
112	1	1	Dr David Ferry The Royal Wolv	21	1	1	B52 8HW	21	3	3	CV	
113	1	1	Dr Emilie Wilkes Derby Hospital	28	1	1	CB2 2QQ	28	3	3	DE	
114	+	1	Dr Hugo Ford, Oncology Centre	29	1	1	CF14 4XW	29	3	4	GL	
116	1	1	Dr lan Judson Clinical Pharmac	30	1	1	CH63 4JY	30	3	3	HU	
				31	1	1	CV2 2DX	31	3	4	L	1
24	J	ase	n Chooramun Ap	32	1	1	EH4 2XR	32	3	3	PO	b level 1
								33	2	2	BD	1
								24	2	2	84	-
								- 34	1	1.0	DI	E



Google Fusion and Google Maps to build the Map



Clinical Trial Locations Geographical Mapping Learnings

•Mapping sites below country level is still a challenge

•'non- standard' English characters in CT.gov must be manually curated

Non-standardisation entry of address fields in CT.gov
i.e. Research Triangle Park, NC- city is not listed- Raleigh. This is correctly mapped in Google Geocharts but may not be in other mapping tools.

•BizInt Pipeline latest version (3.6.1) will extract cities and postcodes from CT.gov

•With 3.6.1, cities and postcodes from CTT can be extracted but entails many stepsthe keyword feature in Vantage Point is used to create the 'vocabulary' and then export back to BizInt.

•Sitetrove generates decent maps at state level but one is not able to review the data

•The advantage of using the database features to generate the mappings is that one can click through to the trial information

26 Jasen Chooramun | April 2014



Clinical Trial Timeline Background

•How can we rapidly gain an understanding of the clinical trial landscape from multiple data sources

•By mapping trials onto a visual timeline we can easily gain a temporal overview of competitor trials

•Data on DPP-IV inhibitor trials was search in CT.gov and CTT



Clinical Trial Timeline Process

•TrialTrove and CT.gov data imported and merged in BizInt Smart Charts and Reference Rows

Data sent to VP-SCE

•Further processing

- Date extraction
- Standard vocabulary for status and phase of trial applied
- Sponsors cleaned up

•Visualisation macro used to generate timeline view



II-SDV 2014. Nice

28 Jasen Chooramun | April 2014

VantagePoint – Smart Charts Edition (VP-SCE) Date Extraction

Number of Records:	363	Sou	irce Database:	BizInt Smart Ch	arts Re	ference Rows 1.1	1.1			
Source Date:	Mar 27 2014 11:26		Source File:	\\emea.astraze	neca.ne	t\UK\Alderley Par	k\Users 02\M	PA701Q\Documents\Inf	ormation Scien	ce ISA\BizInt
Field				Number of	Items	% Coverage	Data Type	Meta Tags		
# Arms Acronym Arms Group Type Description Brief Summary Common Trial ID Completion Date Condition Countries Detailed Description Drugs	Create List List Cleanup Thesaurus				11 28 555 353 6 383 382 363 236 55 86 78 319	64% 7% 65% 65% 44% 100% 100% 89% 100% 20% 100%		Parent Child Child Child		
Eligibility Criteria Enrollment	Find and Replace				966 287	74% 100%				
Full Text Link Gender Healthy Volunteers? Interventions Name	Further Processing Extract My Keywords Rename Field	•	:Read A Apply P Author Dates	ll Proper Case Cleanup		100% 93% 67% 74%)-Mmm-VVV	Parent	_	
Type Description Group Last Changed Date Location Details Faciliy	Copy Field Set Data Type Set Meta Tags Delete Field	ŀ	Divide a Divide A Extract (NLP	at Authors Country	•	Convert M/ Convert Ma Convert YY Extract Year	/D/YYYY to Y onth DD, YYY YY-MM-DD t rs	YYY-MM-DD Y to YYYY-MM-DD to YYYYMMDD		
Country City Post Code Maximum Age Minimum Age Num. Locations Num. Recruiting Original Title	View Statistics Zoom	•	Read Af Read Af Read Ur Read Ur Remove	iter - First iter - Last ntil - First ntil - Last	266	Remove Tir 26% 84% 93% 100% 74% 73%	ne	Child		



29 Jasen Chooramun | April 2014

VantagePoint – Smart Charts Edition (VP-SCE) Company Cleanup

Cleanup Sets Detail Window						
tem Name	Num Records	Display				
 Merck KGaA Merck KGaA Merck KGaA Kowa Pharmaceuticals Jiangsu Hengrui Medicine Co Astellas Pharma/OSI Astellas Pharma/OSI Astellas Pharma/OSI Astellas Pharma/OSI Daiichi Sankyo 	148 146 2 12 6 5 1 4 5 2	All items Combined Items Custom Set of Items Custom Set of Items Find Close Matches (50%) Remove All Invert Set Find Find Hegular Expression Add Remove Save as Thesaurus				

VantagePoint – Smart Charts Edition (VP-SCE) Date Clean-up

	# Records	# Instances	Overall Status	Active, Not Recruiting	Completed	Open, Recruiting	Planned	Terminated
1	633	633	Completed					
2	50	50	Terminated					$\mathbf{\nabla}$
3	48	48	Recruiting			\mathbf{V}		
4	29	29	Open			\mathbf{V}		
5	18	18	Not yet recruiting					
6	16	16	Active, not recruiting	$\overline{\mathbf{v}}$				
7	12	12	Planned					
8	8	8	Closed	X				
9	3	3	Withdrawn					
10	1	1	Enrolling by invitation					
11	1	1	Suspended					

	# Records	# Instances	Sponsor(s) (1) (Cleaned) - Con
328	1	1	Laval University - NCT00660075
329	1	1	Laval University - NCT01334229
330	1	1	Lexicon Pharmaceuticals - NCT01441232
331	1	1	LG Life Sciences - NCT01001013
332	1	1	LG Life Sciences - NCT01426399



Clinical Trial Timeline Timeline Macro

Select the field to chart: Sponsor(s) (1) (Cleaned) - Common Trial ID 💌	
Select a Group	Common Trial ID Timeine
Takeda Key Select Start Year Select Completion Date: Dates/Extract Years Completion Date: Dates/Extract Years Select Phase Field Select Timeline Colors Phase Colors #1 Phase Colors #2 Phase Colors #3	2002 2013 2004 2005 2006 2017 2006 2019 2011 2012 2019 2014 2015 NCTORDERVE
	Cancel OK

32 Jasen Chooramun | April 2014

Clinical Trial Timeline Trial Timeline by Phase

•Landscape of Takeda's DPP-IV inhibitor trials

•Colour reflects the trial phase





Clinical Trial Timeline Trial Timeline by Trial Status



34 Jasen Chooramun | April 2014



Clinical Trial Timeline Trial Timeline by Patient Population







Clinical Trial Timeline TIBCO Spotfire



Wish List

Improvements to make these analyses easier

 Transfer NCT numbers from a TrialTrove result set into CT.gov

• Freeze trial timeline and legend

 Dates – clients think by quarters as opposed to years in the timelines

 Improve recognition of non-Western language characters – e.g. Sjögrens



•Multiple clinical trial resources are needed to gain accurate insights into the clinical landscape

 Combinantion of Smart Charts and VP-SCE is a powerful tool kit to harmonize trial data across different sources

•You do need to invest time in the data cleansing process

•Geo Mapping is simplified extracting the trials location information in a multistep procedure.



38 Jasen Chooramun | April 2014

Team Involved



Jasen Chooramun, AZ



Jeanette Eldridge, AZ



So Man, AZ







Matt Eberle, BizInt



John Willmore, BizInt



Diane Webb, BizInt

Thank you

For more information about AstraZeneca and activities worldwide, visit astrazeneca.com

For more information about BizInt, visit bizint.com

AstraZeneca 秋